Lilly ly3475070
Nettet4. nov. 2024 · A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer. Latest version (submitted January 18, 2024) on ClinicalTrials.gov. A study version is represented by a row in the table. Select two study versions to compare. NettetUne étude de l'inhibiteur de CD73 LY3475070 seul ou en association avec le pembrolizumab chez des participants atteints d'un cancer avancé Une première mondiale multicentrique de phase 1 dans l'étude humaine de l'inhibiteur de CD73 LY3475070 en monothérapie ou en association avec le pembrolizumab chez des patients atteints de …
Lilly ly3475070
Did you know?
NettetLead Sponsor: Eli Lilly and Company Collaboratore: Merck Sharp & Dohme LLC Fonte: Eli Lilly and Company Breve riassunto: Il motivo di questo studio è vedere se l'inibitore CD73 LY3475070 da solo o in combinazione con pembrolizumab è sicuro ed efficace nei partecipanti con cancro avanzato. Nettet10. apr. 2024 · The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced …
NettetDescription: LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).: Targets Nettet1. aug. 2024 · CD73 is a multifunctional ectoenzyme affecting both tumor cells and immune cells. CD73 has been hijacked by TME to promote tumor growth and metastasis. Targeting CD73 and other adenosinergic molecules orchestrates anti-tumor immunity. CD73 blockade achieves synergy in combination with conventional therapy and/or ICB.
NettetLY3475070 Alone or in Combination With Pembrolizumab is now under trials for patients with Advanced Cancer. Chemical Structure LY-3475070. CAS# 2375815-63-5. Product data Instruction. Theoretical Analysis MedKoo Cat#: 207152 Name: LY-3475070 CAS#: 2375815-63-5 Chemical Formula: C15H18N4O2 NettetEli Lilly and Company. Eudract number. 2024-003270-64. Duration of Study in the UK. 3 years, 0 months, 9 days. ... LY3475070 is an orally available drug that works by …
Nettet8. jun. 2024 · LY3475070 is also being tested in a clinical trial as monotherapy or in combination with an anti-PD-1 mAb in patients with advanced-stage solid cancers (NCT04148937).
NettetA Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid … homes for sale in baker caNettetDrug Detail. Drug Name. LY3475070. Trade Name. Synonyms. LY-3475070 LY 3475070. Drug Descriptions. LY3475070 is a CD73 inhibitor, which inhibits conversion of adenosine monophosphate (AMP) to adenosine to prevent suppression of the anti-tumor response (NCI Thesaurus). DrugClasses. homes for sale in baker louisiana 70714homes for sale in baker ranch lake forest caNettet1. jul. 2024 · Abstract. Background: Patients (pts) with EGFRm T790M-negative NSCLC with progressive disease (PD) on an EGFR TKI have limited therapy options. CD73 … homes for sale in bakersfield ca 93306NettetEli Lilly and Company. Eudract number. 2024-003270-64. Duration of Study in the UK. 3 years, 0 months, 9 days. ... LY3475070 is an orally available drug that works by binding/inhibiting a protein on the outside of the CD73 molecule. LY3475070 has been studied in laboratory and animal trials. hippomartNettet31. okt. 2024 · The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and ... (1-877-285-4559) or 1-317-615-4559 … homes for sale in bakersfield ca 93313Nettet16. jan. 2024 · The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced … hippo manager software inccareers